1
|
Pecha S, Burger H, Chung DU, Möller V, Madej T, Maali A, Osswald B, De Simone R, Monsefi N, Ziaukas V, Erler S, Perthel M, Wehbe MS, Ghaffari N, Sandhaus T, Busk H, Schmitto JD, Bärsch V, Easo J, Albert M, Treede H, Nägele H, Zenker D, Hegazy Y, Gessler N, Knaut M, Reichenspurner H, Willems S, Butter C, Hakmi S. Safety and Efficacy of Laser Lead Extraction in Octo- and Nonagenarians: A Subgroup Analysis from the GALLERY Registry. Thorac Cardiovasc Surg 2023. [DOI: 10.1055/s-0043-1761823] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/22/2023]
Affiliation(s)
- S. Pecha
- University Medical Center Hamburg-Eppendorf, Hamburg, Deutschland
| | - H. Burger
- Kerckhoff Klinik Bad Nauheim, Bad Nauheim, Deutschland
| | - D. U. Chung
- Asklepios Klinik St. Georg, Hamburg, Deutschland
| | - V. Möller
- Immanuel Herzzentrum Brandenburg, Bernau bei Berlin, Deutschland
| | - T. Madej
- University Hospital Carl Gustav Carus Dresden Heart Center, Dresden, Deutschland
| | - A. Maali
- Herzzentrum, Coswig (Anhalt), Deutschland
| | - B. Osswald
- Johanniter-Krankenhaus Duisburg-Rheinhausen, Duisburg, Deutschland
| | - R. De Simone
- Universitätsklinikum Heidelberg Klinik für Herzchirurgie, Heidelberg, Deutschland
| | - N. Monsefi
- Helios Klinikum Siegburg, Siegburg, Deutschland
| | - V. Ziaukas
- Schüchtermann-Klinik, Bad Rothenfelde, Deutschland
| | - S. Erler
- Department of Cardiothoracic Surgery, Bad Bevensen, Deutschland
| | - M. Perthel
- Heart Centre Bad Segeberg, Bad Segeberg, Deutschland
| | - M. S. Wehbe
- Sana Herzchirurgie Stuttgart GmbH, Stuttgart, Deutschland
| | - N. Ghaffari
- Helios Heart Surgery Clinic Karlsruhe, Karlsruhe, Deutschland
| | | | - H. Busk
- Uniklinik Magdeburg, Magdeburg, Deutschland
| | - J. D. Schmitto
- Medizinische Hochschule Hannover (MHH), Hannover, Deutschland
| | - V. Bärsch
- St. Marien-Krankenhaus Siegen—Klinik für Allgemein-, Viszeral- und Gefäßchirurgie, Siegen, Deutschland
| | - J. Easo
- Hospital Oldenburg, Oldenburg, Deutschland
| | - M. Albert
- Robert-Bosch Hospital, Stuttgart, Deutschland
| | - H. Treede
- Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Deutschland
| | - H. Nägele
- Albertinen Krankenhaus, Hamburg, Deutschland
| | - D. Zenker
- Robert-Koch-Str. 40, Göttingen, Deutschland
| | - Y. Hegazy
- MediClin Heart Center Lahr/Baden, Lahr/Schwarzwald, Deutschland
| | - N. Gessler
- Asklepios Klinik St. Georg, Hamburg, Deutschland
| | - M. Knaut
- Herzzentrum Dresden Universitätsklinik, Herzchirurgie, Dresden, Deutschland
| | | | - S. Willems
- Asklepios Klinik St. Georg, Hamburg, Deutschland
| | - C. Butter
- Immanuel Herzzentrum Brandenburg, Bernau bei Berlin, Deutschland
| | - S. Hakmi
- Asklepios Klinik St. Georg, Hamburg, Deutschland
| |
Collapse
|
2
|
Pecha S, Burger H, Möller V, Madej T, Osswald B, Maali A, De Simone R, Monsefi N, Ziaukas V, Erler S, Elfarra H, Perthel M, Hemmer W, Ghaffari N, Sandhaus T, Busk H, Schmitto J, Bärsch V, Easo J, Treede H, Albert M, Nägele H, Zenker D, Hegazy Y, Ahmadi D, Ehrlich W, Knaut M, Reichenspurner H, Butter C, Hakmi S. The German Laser Lead Extraction Registry: GALLERY. Thorac Cardiovasc Surg 2019. [DOI: 10.1055/s-0039-1678794] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Affiliation(s)
- S. Pecha
- Universitäres Herzzentrum Hamburg, Klinik und Poliklinik für Herz- und Gefäßchirurgie, Hamburg, Germany
| | - H. Burger
- Kerckhoff-Klinik, Herzchirurgie, Bad Nauheim, Germany
| | - V. Möller
- Herzzentrum Brandenburg, Kardiologie, Bernau bei Berlin, Germany
| | - T. Madej
- Herzzentrum Dresden, Klinik für Herzchirurgie, Dresden, Germany
| | - B. Osswald
- Universitätsklinikum Düsseldorf, Klinik für Kardiovaskuläre Chirurgie, Düsseldorf, Germany
| | - A. Maali
- Herzzentrum Coswig, Herz- und Gefäßchirurgie, Coswig, Germany
| | - R. De Simone
- Universitätsklinikum Heidelberg, Klinik für Herzchirurgie, Heidelberg, Germany
| | - N. Monsefi
- Universitätsklinikum Frankfurt, Thorax-, Herz- und Thorakale Gefäßchirurgie, Frankfurt am Main, Germany
| | - V. Ziaukas
- Schüchtermann-Klinik, Herzchirurgie, Bad Othenfelde, Germany
| | - S. Erler
- Herz- und Gefässzentrum, Klinik für Herz-Thorax-Chirurgie, Bad Bevensen, Germany
| | - H. Elfarra
- Universitätsklinikum Marburg, Herz- und Thorakale Gefäßchirurgie, Marburg, Germany
| | - M. Perthel
- Herzzentrum Bad Segeberg, Herzchirurgie, Bad Segeberg, Germany
| | - W. Hemmer
- Sana Herzchirurgie Stuttgart, Hemmer, Stuttgart, Germany
| | - N. Ghaffari
- Helios Klinik für Herzchirurgie Karlsruhe, Herzchirurgie, Karlsruhe, Germany
| | - T. Sandhaus
- Universitätsklinikum Jena, Klinik für Herz- und Thoraxchirurgie, Jena, Germany
| | - H. Busk
- Universitätsklinikum Magdeburg, Herz- und Thoraxchirurgie, Magdeburg, Germany
| | - J. Schmitto
- Medizinische Hochschule Hannover, Klinik für Herz-, Thorax-, Transplantations- und Gefäßchirurgie, Hannover, Germany
| | - V. Bärsch
- Helios Klinikum Siegburg, Herzchirurgie und Thoraxchirurgie, Siegburg, Germany
| | - J. Easo
- Klinikum Oldenburg, Universitätsklinik für Herzchirurgie, Oldenburg, Germany
| | - H. Treede
- Universitätsklinikum Halle (Saale), Universitätsklinik und Poliklinik für Herzchirurgie, Halle (Saale), Germany
| | - M. Albert
- Robert-Bosch-Krankenhaus, Herz- und Gefäßchirurgie, Stuttgart, Germany
| | - H. Nägele
- Albertinen Herz- und Gefäßzentrum, Herzinsuffizienz- und Devicetherapie, Hamburg, Germany
| | - D. Zenker
- Universitätsmedizin Göttingen, Klinik für Thorax-, Herz- und Gefäßchirurgie, Göttingen, Germany
| | - Y. Hegazy
- Herzzentrum Lahr, Herz-, Thorax- und Gefäßchirurgie, Lahr, Germany
| | - D. Ahmadi
- Universitäres Herzzentrum Hamburg, Klinik und Poliklinik für Herz- und Gefäßchirurgie, Hamburg, Germany
| | - W. Ehrlich
- Kerckhoff-Klinik, Herzchirurgie, Bad Nauheim, Germany
| | - M. Knaut
- Herzzentrum Dresden, Klinik für Herzchirurgie, Dresden, Germany
| | - H. Reichenspurner
- Universitäres Herzzentrum Hamburg, Klinik und Poliklinik für Herz- und Gefäßchirurgie, Hamburg, Germany
| | - C. Butter
- Herzzentrum Brandenburg, Kardiologie, Bernau bei Berlin, Germany
| | - S. Hakmi
- Universitäres Herzzentrum Hamburg, Klinik und Poliklinik für Herz- und Gefäßchirurgie, Hamburg, Germany
| |
Collapse
|
3
|
Lauschke J, Busch M, Haverkamp W, Bulava A, Schneider R, Andresen D, Nägele H, Israel C, Hindricks G, Bänsch D. New implantable cardiac monitor with three-lead ECG and active noise detection. Herz 2016; 42:585-592. [DOI: 10.1007/s00059-016-4492-7] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2016] [Revised: 09/27/2016] [Accepted: 10/04/2016] [Indexed: 01/14/2023]
|
4
|
Nägele H, Lauterwein M, Castel M. Gas exchange and central hemodynamics in patients with severe heart failure. Int J Cardiol 2010; 141:109-11. [DOI: 10.1016/j.ijcard.2008.11.061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/18/2008] [Accepted: 11/15/2008] [Indexed: 10/21/2022]
|
5
|
Nägele H, Behrens S. Response to the Letter of de Cock et al. Pacing Clin Electrophysiol 2007. [DOI: 10.1111/j.1540-8159.2007.00859_2.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
6
|
Abstract
Cardiac resynchronization therapy (CRT) is a new method for the correction of inter- and/or intraventricular conduction delays of patients with heart failure. The long-term impact of CRT on central hemodynamics is not fully characterized. We performed complete right heart catheterization studies in 31 patients receiving a CRT device pre and 6 months after implantation. Most of the patients improved in their NYHA stage, their LVEF, and in parallel showed reduced right atrial (RA) pulmonary artery (PA) and pulmonary capillary wedge (PCW) pressures and pulmonary vascular resistance both at rest and at 25 watts. In addition, we found a reduction in heart rate accompanied by an increased mean arterial pressure both at rest and at 25 watts. Accordingly, brain natriuretic peptide levels (BNP) were lowered. It was concluded that, besides other well-known effects on ventricular coordination, central hemodynamics after 6 months were improved during CRT.
Collapse
Affiliation(s)
- H Nägele
- Medizinische Klinik, Krankenhaus Reinbek, St. Adolfstift, Hamburger Str. 41, D-21465 Reinbek.
| | | | | |
Collapse
|
7
|
Azizi M, Nägele H. Inappropriate shock during left ventricular threshold measurement in a patient with coexisting ICD and a biventricular pacemaker. Herzschrittmacherther Elektrophysiol 2007; 18:101-4. [PMID: 17646942 DOI: 10.1007/s00399-007-0563-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2007] [Accepted: 02/23/2007] [Indexed: 05/16/2023]
Abstract
Cardiac resynchronization therapy (CRT) using coronary sinus (CS) leads for biventricular stimulation is an established method for the therapy of congestive heart failure (CHF) in the case of inter- or intraventricular conduction delays. There are some patients having two separate devices: an ICD and a biventricular pacemaker. This case report describes an unusual interaction of these systems: an inappropriate VVI defibrillator shock during left ventricular threshold measurement in a biventricular pacemaker implanted on the other side.
Collapse
Affiliation(s)
- M Azizi
- St. Adolfstift, Medical Clinic, Hamburgerstr. 41, 21465 Reinbek, Germany
| | | |
Collapse
|
8
|
Nägele H, Hashagen S, Azizi M, Behrens S, Castel MA. Analysis of terminal arrhythmias stored in the memory of pacemakers from patients dying suddenly. ACTA ACUST UNITED AC 2007; 9:380-4. [PMID: 17434892 DOI: 10.1093/europace/eum040] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
AIMS Stored electrograms or marker channels are available in most of modern cardiac pacemaker models. We sought to analyse these information to uncover terminal events of pacemaker patients dying suddenly. Method and results We made post-mortem pacemaker (PM) interrogations in 19 patients dying suddenly out of hospital between the years 1997 and 2005 (mean age 59 +/- 13 years, 90% males). The systems had activated arrhythmia monitoring algorithms. Indications of pacing were sick sinus syndrome in seven, AV-block in five, and heart failure due to asynchrony in seven cases. The interrogated pacemakers were CHORUS 7034 (n = 12), CONTAK TR (n = 2), and INSYNC III (n = 5). For interpretation stored marker channels and electrograms were analysed. The mean observation time after PM implantation prior death was 2.11 +/- 1.44 years, the mean left ventricular ejection fraction from the last available echo examination in the year prior death was 27.5 +/- 8%, mean age was 63 +/- 12 years. In 17/19 cases (89%), a tachycardia (most likely ventricular tachycardia) was found correlating to the time of death. The mean cycle length of the terminal arrhythmia was 307 +/- 144 (250-344) ms, corresponding to a heart rate of 195 +/- 95 (174-240) bpm. We found no evidence of specific pacemaker-related problems such as electronic failure, battery depletion, or undersensing. CONCLUSIONS Post-mortem analysis of arrhythmia monitoring of pacemaker patients revealed tachycardias (most likely ventricular tachycardia) to be related to sudden death. These findings give some insight in mechanisms of terminal events in this group.
Collapse
Affiliation(s)
- H Nägele
- St Adolfstift, Medical Clinic, Reinbek, Germany, Hamburger Str. 41, D-21465 Hamburg.
| | | | | | | | | |
Collapse
|
9
|
Abstract
AIMS Coronary sinus (CS) lead implantation is a technically challenging procedure owing to variable vein anatomies and a high dislocation rate. Therefore, CS lead technology has undergone evolutionary changes during the last 10 years. The mode of fixation has been a passive one up to now. We want to describe our first clinical experience with the newly available active fixation lead 4195 in terms of dislocation rate and stability of thresholds compared with conventional models. METHODS AND RESULTS From 1999 to February 2007, we implanted 403 CS leads in 368 patients. Leads were categorized into three different groups on the basis of their fixation mechanism: straight (Easytrak I and Situs OTW; n = 54), curved (Attain 4193 and 4194, Corox, Aescula, Situs ULD; n = 308), and active (Attain 4195; n = 41). Operative and follow-up data were prospectively noted and checked for significance between groups during the first 3 months after implantation. Kaplan-Meier analysis of long-term lead function was also performed. Straight and curved CS leads suffered from significantly more dislocations compared with active fixation (P < 0.001). The active fixation lead (4195) has a stable threshold over time compared with a significant rise after 24 h and thereafter in straight (62%) and curved leads (20%). However, retraction of an active fixation CS lead may be a difficult issue as outlined in two cases requiring pullback of a 4195 lead owing to phrenic nerve stimulation (one unsuccessful despite vigorous traction). CONCLUSION The active fixation lead 4195 using retention lobes yielded stable thresholds over time and seems to be superior to conventional leads in terms of dislocation. However, extraction may be a difficult or even impossible task.
Collapse
Affiliation(s)
- H Nägele
- Medical Department, St Adolfstift, Hamburgerstr. 41, D-21465 Reinbek, Germany.
| | | | | | | | | |
Collapse
|
10
|
Abstract
Rhabdomyolysis is a well known side effect of statin therapy. Several drugs may increase its risk by drug-drug interactions. In particular, patients with heart disease receive more and more different compounds to cope with all the pathomechanisms involved and may therefore be of high risk for side effects. We report a case of rhabdomyolysis in a patient with heart failure on a multi-drug regimen caused by a drug interaction between chronic statin therapy (simvastatin), amiodarone and newly administrated digitoxin. The patient recovered fully after cessation of simvastatin therapy, the other drugs were given continuously. Potential mechanisms of this event are discussed. Most interesting in this case is that rhabdomyolysis occurred only after starting digitoxin after long-term therapy with the statin.
Collapse
Affiliation(s)
- H Nägele
- St. Adolfstift Medical Clinic, Reinbek, Germany.
| | | | | | | |
Collapse
|
11
|
Nägele H, Hashagen S, Azizi M, Behrens S, Castel MA. Long-term hemodynamic benefit of biventricular pacing depending on coronary sinus lead position. Herzschrittmacherther Elektrophysiol 2006; 17:185-90. [PMID: 17211748 DOI: 10.1007/s00399-006-0533-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2006] [Accepted: 11/21/2006] [Indexed: 05/13/2023]
Abstract
BACKGROUND Acute studies in cardiac resynchronization therapy (CRT) showed that hemodynamic effects may depend on the coronary sinus (CS) lead position. However, there are no data on the longterm effect of CS lead position. METHODS In 45 heart failure patients with left bundle branch block and QRS >150 ms (age 59+/-10 years, 17 dilative cardiomyopathy, 23 ischemic, 5 valvular), biventricular pacemakers were implanted. CS leads were positioned in posterior (P, n=15), lateral (L, n=19) or, if no other option available, anterior (A, n=11) side branches. Before and 6 months after implantation, clinical state, echocardiography, brain natriuretic peptide (BNP) and right heart catheterization were evaluated. RESULTS Baseline parameters were similar between groups. After 6 months, there were 32/34 responders in groups P and L compared to 7/11 responders in group A (94 vs groups P and L: Arterial pressure +8 and +9% vs +2%; PCWP -23 and -15% vs -4%, pulmonary pressure -18 and -12% vs -3% (p<0.01 for A vs P+L); cardiac index +21 and +12% vs +11% (p=0.03 for A vs P). BNP was reduced by 55, 35, and 27% (p=0.05 for A vs P). Ejection fraction increased in P and L by 40 and 41%, respectively, but only by +19% in A (p<0.03 for A vs P+L). CONCLUSION Chronic CRT improves ejection fraction, BNP and hemodynamic measurements predominantly in patients with lateral and posterior CS lead positions. Anterior lead positions should be avoided.
Collapse
Affiliation(s)
- H Nägele
- Gustav-Adolf-Stift, 21465 Reinbek, Germany.
| | | | | | | | | |
Collapse
|
12
|
Nägele H, Azizi M. Inappropriate ICD discharge induced by electrical interference from a physio-therapeutic muscle stimulation device. Herzschrittmacherther Elektrophysiol 2006; 17:137-9. [PMID: 16969728 DOI: 10.1007/s00399-006-0527-8] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2005] [Accepted: 03/15/2006] [Indexed: 05/11/2023]
Abstract
This report illustrates the case of a patient with an implantable cardioverter defibrillator (ICD) who during physiotherapy with transcutaneous electrical stimulation of the lumbar musculature perceived a shock discharge by the ICD. Analysis of the stored electrogram showed inappropriate therapy due to electromagnetic interference with the external stimulation. Patients as well as physiotherapists should be informed about this potential interaction to avoid such iatrogenic, inappropriate ICD therapy.
Collapse
Affiliation(s)
- H Nägele
- St. Adolfstift, Medical Clinic, Hamburger Str. 41, 21465, Reinbek, Germany
| | | |
Collapse
|
13
|
Nägele H, Ergin M, Azizi M, Behrens S, Jäckle S. Reversible impairment of myocardial function in Hanta virus infection – direct viral effect? Clin Res Cardiol 2006; 95:554-6. [PMID: 16845572 DOI: 10.1007/s00392-006-0419-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/01/2006] [Accepted: 06/07/2006] [Indexed: 10/24/2022]
|
14
|
Nägele H, Azizi M, Hashagen S, Behrens S. Long-term follow-up of a malpositioned ventricular pacing lead via the aortic valve. Clin Res Cardiol 2006; 95:488-91. [PMID: 16799878 DOI: 10.1007/s00392-006-0405-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/20/2006] [Accepted: 05/11/2006] [Indexed: 10/24/2022]
|
15
|
Azizi M, Castel MA, Behrens S, Rödiger W, Nägele H. Experience with coronary sinus lead implantations for cardiac resynchronization therapy in 244 patients. Herzschrittmacherther Elektrophysiol 2006; 17:13-8. [PMID: 16547655 DOI: 10.1007/s00399-006-0502-4] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2005] [Accepted: 12/29/2005] [Indexed: 05/07/2023]
Abstract
INTRODUCTION Cardiac resynchronization therapy (CRT) using coronary sinus (CS) leads is a new method for the therapy of congestive heart failure (CHF). Because the intervention is more complex than regular pacemaker implantations, information on the feasibility and side effects of this method are of interest. METHODS From 1999 to June 2005, CRT implantations were attempted in 244 patients (pts; mean age 64+/-12 years, range 14-90 years), 82% were male, 44% had coronary artery disease, 29% were in atrial fibrillation, 71 had preexisting pacemakers. RESULTS In 97% of the pts the intervention was successful (27% of the systems with defibrillation capabilities). In 285 interventions, 255 CS leads were positioned according to CS vein anatomy in 130 posterolateral, 97 anterolateral and 28 anterior side branches (16 patients received 2 CS leads). Over-the-wire leads were used in 88%, 71% were additionally preshaped. We observed no mortality but 37 complications (12.5%): CS dissection in 9, CS perforation in 1, ventricular fibrillation in 4, asystole in 5, pulmonary edema in 1, pneumothorax in 2, need for early CS lead revision in 19 (dislodgement n=7, phrenic nerve stimulation n=12) and infection with explantation in 2 cases. An improvement in NYHA functional class was found in 88% of pts (only 55% if anterior lead position). CONCLUSION Perioperative complications during CS lead implantation occur in 10-15% of cases. Most patients responded well to CRT. Patients should be informed about the possible need for a reoperation. During implantation, immediate defibrillation and stimulation capabilities must be available. Anterior lead positions should be avoided.
Collapse
Affiliation(s)
- M Azizi
- Krankenhaus Reinbek, St. Adolfstift, Medical Clinic, Hamburger Str. 41, 21465, Reinbek, Germany
| | | | | | | | | |
Collapse
|
16
|
Treede H, Nägele H, Reichenspurner H. Laser lead extraction of pacemaker or ICD leads in patients with lead infections and/or lead dysfunction is a save and efficative method even in patients with subclavian vein occlusion and a need for vein recanalization. Thorac Cardiovasc Surg 2006. [DOI: 10.1055/s-2006-925775] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
17
|
Wagner F, Nägele H, Castel Lavilla M, Tugtekin S, Matschke K, Knaut M, Reichenspurner H. Reduction of long-term malignoma incidence by single dose ATG-induction after heart transplantation: a two center study. Thorac Cardiovasc Surg 2005. [DOI: 10.1055/s-2005-861918] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
18
|
Bechtel M, Fischlein T, Krabatsch T, Nägele H, Osswald B, Schönburg M, Scholz F, Stamm C, Stripling J, Sievers H, Bartels C. Intraoperative hemofiltration exhibits no clinical benefit in patients with end-stage renal failure undergoing cardiac surgery. A multicenter study. Thorac Cardiovasc Surg 2005. [DOI: 10.1055/s-2005-862048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
19
|
Bechtel M, Fischlein T, Krabatsch T, Nägele H, Osswald B, Schönburg M, Scholz F, Stamm C, Stripling J, Sievers H, Bartels C. An analysis of the risk factors for perioperative mortality in patients with end-stage renal failure undergoing cardiac surgery: a multicenter study. Thorac Cardiovasc Surg 2005. [DOI: 10.1055/s-2005-861965] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
20
|
Nägele H, Castel MA, Deutsch O, Wagner FM, Reichenspurner H. Heart transplantation in a patient with multiple sclerosis and mitoxantrone-induced cardiomyopathy. J Heart Lung Transplant 2004; 23:641-3. [PMID: 15135385 DOI: 10.1016/s1053-2498(03)00307-3] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2003] [Revised: 06/17/2003] [Accepted: 06/17/2003] [Indexed: 10/26/2022] Open
Abstract
We describe a 30-year-old man with end-stage heart failure after therapy with mitoxantrone for multiple sclerosis. A successful orthotopic heart transplantation was performed when intensified medical therapy failed to improve the patient's hemodynamics. In spite of the severe underlying disease he did well on dual immunosuppression with methylprednisone and cyclosporine. Neurologic symptoms remained stable throughout the procedure and, after 2 months, he resumed preoperative ambulatory status. Eight years after the operation, the patient is now in New York Heart Association (NYHA) Class I status. Using canes, he is able to walk short distances. Repeated urinary tract infections caused by Escherichia coli became a problem, but have been controlled by long-term oral antibiotic prophylaxis with trimethoprim.
Collapse
Affiliation(s)
- H Nägele
- Department of Cardiovascular Surgery, University Clinic Eppendorf, Hamburg, Germany.
| | | | | | | | | |
Collapse
|
21
|
Nägele H, Schomburg R, Petersen B, Rödiger W. Dual chamber pacing in patients with severe heart failure on beta blocker and amiodarone treatment: preliminary results of a randomised study. Heart 2002; 87:566-7. [PMID: 12010943 PMCID: PMC1767124 DOI: 10.1136/heart.87.6.566] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
22
|
Abstract
BACKGROUND Pacemaker infection or some lead dysfunctions are an indication for removal of all foreign material. The use of laser energy is a new method for extraction of fixed leads that have been in place for a long time. There are only a few reports on results and complications of laser extraction in comparison to conventional methods. Therefore, this study compares results of laser lead extraction and conventional methods. METHODS Since January 1999 we have made use of the laser lead extraction system of Spectranetics, Inc. Inner traction of the leads was performed using a "lead locking device" (LLD) and for laser application 12, 14 und 16 French "laser sheaths" were used. As the energy source, an excimer laser device was used (CVX-300). The intervention was performed under heart-lung machine backup. Results of the laser procedure in 24 patients and 45 leads (including 3 defibrillator leads) are compared to results of manual traction (23 patients, 53 leads), traction devices (24 patients, 38 leads), snare catheters (6 patients, 6 leads) and thoracotomy (5 patients, 9 leads) from the years 1995-1998. RESULTS The mean operation time of the laser method (93 +/- 50 min) was not significantly different from manual traction (82 +/- 48 min,) or traction devices (100 +/- 45 min). The mean fluoroscopy time (9.4 +/- 50 min) was similar to traction devices (8.4 +/- 5 min, p < 0.05). In one patient a percardial tamponade developed with the need for urgent thoracotomy. This patient died on the fourth postoperative day due to cerebral hypoxia. The other 23 patients had an uneventful course. All but one lead could be removed without fragmentation, including a malpositioned lead in the left ventricle (success rate 96%). In 62 patients and 97 conventional extractions (53x manual, 38x device, 6x snare) from 1995-1998, one fatal (sepsis due to lead fragmentation) and four severe complications developed (pericardial tamponade, pulmonary abscess, pulmonary embolism, sepsis). In 15/62 patients with conventional methods, lead fragments remained (success rate 76%). Of five patients from 1995-1998, in whom leads with vegetations or tricuspid valve insufficiency were removed by thoracotomy and cardiopulmonary bypass, one patient died perioperatively. CONCLUSIONS In contrast to conventional methods, excimer laser pacemaker or defibrillator lead extraction allows total removal of all foreign material. This prevents late complications from lead fragments left in place. However, life-threatening complications can occur with conventional as well as with the laser method. Therefore, this intervention should be done only in specialized centers using extended monitoring (invasive blood pressure, TEE).
Collapse
Affiliation(s)
- H Nägele
- Herzchirurgie Universitätsklinikum Hamburg-Eppendorf Martinistr. 52 20246 Hamburg, Germany.
| | | | | |
Collapse
|
23
|
Nägele H, Schneider JC, Knobelsdorff GV, Petersen B, Rödiger W. Excimer laser-assisted extraction of an infected bipolar left ventricular pacing lead implanted 10 years ago. Pacing Clin Electrophysiol 2001; 24:388-90. [PMID: 11310312 DOI: 10.1046/j.1460-9592.2001.00388.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Routine intraoperative transesophageal echocardiography (TEE) revealed a previously undiscovered ventricular positioning of an infected ventricular lead left in place for 10 years. This case report describes successful removal of this lead from the left ventricle by means of excimer laser and discusses some important aspects to be considered.
Collapse
Affiliation(s)
- H Nägele
- Department of Cardiothoracic Surgery, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
| | | | | | | | | |
Collapse
|
24
|
Nägele H, Rödiger W. Response to the letter to the editor. Eur J Heart Fail 2001. [DOI: 10.1016/s1388-9842(00)00128-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Affiliation(s)
- H. Nägele
- Klinik Chirurgische Abteillung für Thorax-Herz- und Gefäβchirurgic Martinistr.; 52 20246 Hamburg Germany
| | - W. Rödiger
- Klinik Chirurgische Abteillung für Thorax-Herz- und Gefäβchirurgic Martinistr.; 52 20246 Hamburg Germany
| |
Collapse
|
25
|
Abstract
The implantation of fresh or cryopreserved human heart valves (homografts) in aortic position is a tool in cardiac surgery since 30 years. Homografts are attractive alternatives to the implantation of mechanical or xenobiological prostheses, because anticoagulation can be avoided and a near normal anatomy can be restored. Physicians should know about the several kinds of grafts and operative techniques to adequately take care of the patients in follow-up. This overview on the literature covers methods of harvesting, preparation and conservation of homografts according to standard protocols of the European Homograft Bank in Brussels. Their use in the therapy of human valvular disease is discussed with special emphasis to operative techniques (subcoronary, root) and the Ross procedure and in pediatric surgery. Complications and aspects of postoperative care are discussed including immunologic phenomena. Homografts are useful tools for aortic valve replacement, especially in juveniles, in the presence of contraindications for anticoagulation and in endocarditis. Whereas aortic homografts have excellent long-term results, pulmonic homografts show a significant rate of malfunction. Further studies should be performed to clarify the role of the Ross operation or stentless xenografts compared to homografts in aortic position. In pediatric cardiac surgery homografts are of value especially for the reconstruction of the right ventricular outflow tract. Homografts in mitral position show disappointing results up to now. The major limitation in the use of homografts is the mismatch of availability and request, therefore homografts can only be used for the above mentioned special indications.
Collapse
Affiliation(s)
- H Nägele
- Abteilung für Thorax- Herz- und Gefässchirurgie, Universitätskrankenhaus Hamburg-Eppendorf.
| | | | | | | |
Collapse
|
26
|
Abstract
BACKGROUND Carvedilol and at least in some studies, amiodarone have been shown to improve symptoms and prognosis of patients with heart failure. There are no reports on the outcome of combined treatment with both drugs on top of angiotensin-converting enzyme inhibitors (ACEI), diuretics and digitalis. METHODS AND RESULTS In 109 patients with severe heart failure submitted for heart transplantation at one single center between the years 1996 and 1998 [left ventricular ejection fraction (LVEF) 24.6+/-11%, 85% males, 52% idiopathic dilated cardiomyopathy (DCM), mean observation time 1. 9+/-0.4 years] a therapy with low-dose amiodarone (1000 mg/week) plus titrated doses of carvedilol (target 50 mg/day) was instituted. In addition, patients received a prophylactic dual chamber pacemaker (PM) in order to protect from bradycardia and for continuous holter monitoring. The devices were programmed in back-up mode with a basal rate of 40 i.p.m. with a hysteresis of 25%. Significantly, more patients were in sinus rhythm after 1 year than at study entry (85% vs. 63%, P<0.01). In 47 patients, under therapy over at least 1 year, the resting heart rate fell from 90+/-19 to 59+/-5 b.p.m. (P<0.001). Ventricular premature contractions in 24-h holter ECGs were suppressed from 1.0+/-3 to 0.1+/-0.3%/24 h (P167 b.p.m. detected by the pacemaker (1.2+/-2.8 episodes/patient/3 months vs. 0.3+/-0.8 episodes/patient/3 months after 1 year (P<0.01). The LVEF increased from 26+/-10 to 39+/-13% (P<0.001). NYHA class improved from 3. 17+/-0.3 to 1.8+/-0.6 (P<0.001) as well as right heart catheterization data. From the total cohort, seven patients (6%) developed symptomatic documented bradycardic rhythm disturbances requiring reprogramming of their pacemakers to DDD(R)/VVI(R) mode with higher basic rates. Two of these patients developed AV block, four sinu-atrial blocks or sinus bradycardia and one patient had bradycardic atrial fibrillation. During the observation period five patients died (3 sudden, 1 due to heart failure and 1 due to mesenteric infarction). Two patients had undergone heart transplants. The 1-year survival rate (Kaplan-Meier) without transplantation was 89%. Compared to historic control patients with amiodarone only (n=154) or without either agent (n=283) this rate was 64 and 57% (P<0.01). CONCLUSIONS Heart failure patients benefit from a combined therapy with carvedilol and amiodarone resulting in a markedly improved NYHA stage, an increase in LV ejection fraction, a stabilization of sinus rhythm, a significant reduction in heart rate, a delay of electrical signal conduction and a suppression of ventricular ectopies. Approximately 6% of patients under such a regime became pacemaker-dependent in the first year. Compared to historic controls prognosis was better and the need for heart transplantation was lower. The exact role of either agent in combination or alone should be clarified in larger randomized studies.
Collapse
Affiliation(s)
- H Nägele
- Abt. Thorax- Herz- und Gefässchirurgie, Universitäts Krankenhaus Hamburg Eppendorf, Martinistr. 52, D-20246, Hamburg, Germany.
| | | | | | | | | |
Collapse
|
27
|
Affiliation(s)
- B Petersen
- Abt. für Herz-, Thorax- und Gefässchirurgie am Universitätskrankenhaus Eppendorf, Martinistr. 52, 20246, Hamburg
| | | | | | | | | | | |
Collapse
|
28
|
Abstract
OBJECTIVE We detected markedly decreased cyclosporin blood levels in a heart-transplanted patient after the gastrointestinal lipase inhibitor orlistat was accidentally added to the treatment program to control for his obesity. Therefore, we determined cyclosporin plasma concentration time kinetics with and without orlistat reexposition in this patient. METHODS Plasma concentration time kinetics of whole blood cyclosporin levels in an obese heart-transplant patient were measured using a standard monoclonal fluorescence polarisation immunoassay. Results were obtained in hourly intervals up to 12 h without and with co-therapy of 3 x 120 mg orlistat (Xenical, Roche Ltd., Switzerland). The orlistat re-exposition was started the day before taking blood samples. RESULTS Cyclosporin trough levels (98 ng/ml vs 52 ng/ml), maximum concentrations (532 ng/ml vs 74 ng/ml) and the area under the blood drug concentration-time curve (2832 ng h ml-1 vs 700 ng h ml-1) were greatly reduced with orlistat. CONCLUSIONS Orlistat markedly decreased blood cyclosporin concentrations, possibly due to an interference with its absorption in the small intestine. To avoid potential dangerous under-immunosuppression, orlistat should not be used in patients taking cyclosporin.
Collapse
Affiliation(s)
- H Nägele
- Abt. Thorax-Herz- und Gefässchirurgie, Universitäts-Krankenhaus Hamburg-Eppendorf, Germany.
| | | | | | | |
Collapse
|
29
|
Abstract
BACKGROUND Because the risk of developing malignant tumors after heart transplantation is approximately 100-fold higher, methods for rapid diagnosis must be developed to allow early and aggressive treatment in these patients. Although tumor markers have been used frequently for surveying already detected cancer, we studied their value in screening for tumors in heart transplant patients. METHODS The levels of the tumor markers CEA, CA19-9, CA125, CA72-4, TPA, TPS, and CYFRA 21-1 were determined prospectively in 3-month intervals in 91 heart transplant patients between 1993 and 1998. RESULTS In eight patients a definite diagnosis of cancer was made during the marker survey (mean observation time 2.85 +/- 1.3 years), including bronchogenic carcinoma in six, renal carcinoma in one, and colon cancer in one. All patients with bronchogenic carcinoma were smokers. The markers had a sensitivity below 60% to detect cancer. Given a 2-fold cutoff level (10 ng/mL), the CEA was the only marker with sufficient specificity (93.8%, only one false-positive result). Two patients were symptom-free even though they had elevated CEA levels. In one of those patients, disseminated intractable cancer was diagnosed at first evaluation, whereas no tumor was found in the other case at first evaluation. Subsequently, by means of fluorodeoxyglucose positron emission tomography, a hypermetabolic region was found in the right upper mediastinum. Control computed tomographic scan 4 weeks after the first investigation showed disseminated intractable disease also in this patient. Another heart transplant patient with colon cancer showed a normalization of the CEA after hemicolectomy and an increase in the CEA when liver dissemination developed. There was a relationship between cardiac death and CA125 and TPS in some heart transplant patients. CONCLUSIONS We conclude that the CEA is the only tumor marker with adequate sensitivity and specificity to detect subclinical malignancies in the follow-up of heart transplant patients. However, because of several limitations (limited diagnostic and therapeutic possibilities and enormous costs), we cannot recommend screening by tumor markers on a regular basis. Because of the elevated risk of cancer in patients who had organ transplantation, further prophylactic measures, especially smoking cessation programs, must be developed. Once a malignancy is diagnosed, tumor markers can help target clinical decisions. Additionally, nonspecific increases in CA125 and TPS levels might be related to nonmalignant circulatory disturbances and cardiac death.
Collapse
Affiliation(s)
- H Nägele
- Chirurgische Klinik, Abt. Thorax-Herz- und Gefässchirurgie, Universitäts-Krankenhaus Hamburg-Eppendorf, Hamburg, Germany.
| | | | | | | |
Collapse
|
30
|
Abstract
BACKGROUND Due to the shortage of donor organs there is a long waiting time for heart transplantation. As a consequence, a high mortality rate on the waiting list diminishes the potential benefit of the procedure. Tailored medical therapy optimized according to the individual patients demands was introduced to select responding HTx candidates for continued management without transplantation. The development of modes of death over time (heart failure, sudden arrhythmic) in this population is unknown. METHODS In 434 elective candidates for heart transplantation, submitted to our institution in the years 1984-1997 (50% coronary artery disease, mean age 51.6 +/- 12 years, 86% males) medical therapy was adjusted according to the results of repeated right heart catherizations. Adjuncts to conventional therapy with ACE inhibitors, digitalis and diuretics were amiodarone, beta-blockers, spironolactone, oral anticogulants, molsidomine or nitrates. Only patients not responding to these measures were processed to HTx. Clinical events (death, mode of death, HTx, resuscitation) were noted and analyzed by the Kaplan-Meier method and related to patients characteristics by multivariance analysis. RESULTS During the mean follow-up of 2.36 +/- 2.4 years only 113 patients (25%) received a donor heart. One hundred-sixteen patients (26%) died without transplantation. Eighty-three (72%) of the deaths were sudden, 24 (20%) due to progression of heart failure and 9 (8%) due to other reasons. A shift from heart failure to sudden death was observed. Including 8 successful resuscitations due to documented VT/VF, there is a 20% risk of having a major arrhythmic event during the first two years of observation. Long-term (>1 year) medical responders had better hemodynamics at entry. Patients who died suddenly had similar clinical and hemodynamic data at entry than patients who needed an early transplant, but were in a comparable NYHA stage before death than long-term medical responders (2.15 +/- 0.8 vs 1.82 +/- 0.6, NS). Patients dying suddenly had significant more ventricular premature beats (1.6 +/- 2.9%/24 hours vs 1.06 +/- 2.8%/24 hours, p < .01) and complex ventricular arrhythmias (7.3 +/- 2.7/24 hours vs 1.98 +/- 5.6/24 hours, p < .01) than long-term responders. Seventy-five percent of all sudden death occurred during the first 2 observation years. CONCLUSIONS The rate of heart failure death in elective candidates for heart transplantation under optimized medical therapy is low when patients are followed closely and transplant can be done rapidly after deterioration is recognized. Sudden death represents the highest risk for most patients. This event occurred predominantly in stable patients under tailored medical therapy without indication for HTx at that time. Our results strongly demand strategies for risk stratification and the investigation of prophylactic measures in this population.
Collapse
Affiliation(s)
- H Nägele
- Department of Thorax-Herz-und Gefässchirurgie, University Hospital Eppendorf, Hamburg, Germany
| | | |
Collapse
|
31
|
Nägele H, Bahlo M, Klapdor R, Rödiger W. Fluctuations of tumor markers in heart failure patients pre and post heart transplantation. Anticancer Res 1999; 19:2531-4. [PMID: 10470189] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
Abstract
BACKGROUND Elevated plasma levels of tumor markers may be caused by diseases other than malignancy, i.e. kidney, liver or circulatory disturbances. These conditions are not well defined, especially since there are only sparse reports on fluctuations of tumor markers related to cardiac function. PATIENTS AND METHODS During our routine pre- and postoperative follow-up tumor marker determinations in heart failure patients were made in order to screen for possible occult neoplasm's which may either be a contraindication or a sequela of heart transplantation. The markers CA 12-5, CEA, CA 19-9, CA 72-4, TPA, TPS and CYFRA 21-1 were determined at three month intervals, besides clinical examination and hemodynamic measurements in a total of n = 118 patients pre- and n = 74 patients post heart transplantation. RESULTS The results were grouped according the clinical status (NYHA-stage 1-4): CA12-5 (29.4 +/- 40.63 omega 151, 174 +/- 345 and 491 +/- 633 U/ml, p < 0.001 between all groups) and TPS (64 +/- 32, 118 +/- 153, 163 +/- 311 and 181 +/- 232 U/ml, p = 0.06 between all groups) were increasingly elevated in NYHA stages 1, 2, 3 or 4 respectively. A direct correlation to right atrial pressure (r = 0.41, p < 0.0001) and pulmonary capillary wedge pressure (r = 0.27, p < 0.001) was only found for CA 12-5. After heart transplantation a normalization of elevated pre-OP levels could be found. Comparable to heart failure patients poor graft function was also associated with elevated levels of CA 12-5 (113 +/- 99 vs 21.6 +/- 31 U/ml, p < 0.0001), CA 72-4 (8.4 +/- 3 vs 3.6 +/- 4, U/ml p = 0.03) and TPS (154 +/- 133 vs 66 +/- 28 U/ml, p < 0.001). The individual time course of the markers, especially of CA 12-5, correlated nicely to clinical events and hemodynamic measurements in some patients. Another finding was that CYFRA 21-1 levels were correlated to renal function. CEA, CA 19-9 and CYFRA 21-1 serum levels were not influenced by circulatory disturbances. CONCLUSION We concluded that the tumor markers CA 12-5 and TPS (but not CEA, CA 19-9 and CYFRA 21-1) are associated with congestion and the clinical course of heart failure and HTx patients. These "nonspecific" changes have to be considered when tumor markers are determined in cancer patients with heart failure. Whether CA 12-5 blood levels may yield additional prognostic information in the management of cardiovascular patients has to be determined in further studies.
Collapse
Affiliation(s)
- H Nägele
- Abt. Thorax- Herz- und Gefässchirurgie, Universitäts-Krankenhaus Eppendorf, Germany.
| | | | | | | |
Collapse
|
32
|
Abstract
BACKGROUND CA 125, known as a marker for ovarian cancer with hypothetical but hitherto uncharacterized biologic functions, was reported to be elevated in some not-well-defined benign conditions. There are no reports on fluctuations of CA 125 related to cardiac function, especially the failing heart and neurohumoral factors such as norepinephrine or atrial natriuretic peptid/e. METHODS AND RESULTS CA 125 blood levels were determined in patients with heart failure before and after heart transplantation (HTx). In 71 patients, parallel determinations of norepinephrine, atrial natriuretic peptide, pulmonary capillary wedge pressure, and right atrial filling pressure were done. CA 125 levels also were prospectively studied in patients with heart failure with stabilization (n = 25) or worsening of the clinical status (n = 9) and after HTx (n = 25). Parallel determinations of the tumor markers CEA, CA 199, CA 153, TPS, and TPA were also done. The results were grouped according to the clinical status (New York Heart Association class) of the patients. CA 125 was significantly correlated with neurohormones and filling pressures. Follow-up investigations revealed a decrease of CA 125 levels after HTx (401 +/- 259 U/L vs 33 +/- 22 U/L, P <.001, n = 25) or stabilization (429 +/- 188 U/L vs 78 +/- 35 U/L, P <.001, n = 25) and an increase during worsening of heart failure (42 +/- 25 U/L vs 89 +/- 32 U/L, P <.01, n = 9). In 4 patients after HTx, unexpected death was preceded by rising CA 125 levels. CEA, CA 199, CA 153, TPS, or TPA did not correlate with heart failure status or clinical events. CONCLUSIONS CA 125 is a marker of the clinical and hemodynamic status and the course of patients with heart failure before and after heart transplantation. The determination of CA 125 serum levels may be an additional tool in the management of these patients. In patients with cancer, these "nonspecific" changes must be considered when CA 125 levels are determined. Whether CA 125 has a specific biologic role in heart failure deserves further studies.
Collapse
Affiliation(s)
- H Nägele
- Department of Thorax-, Herz- und Gefässchirurgie, University Hospital Eppendorf, Germany
| | | | | | | | | |
Collapse
|
33
|
Nägele H, Stubbe HM, Nienaber C, Rödiger W. Results of transmyocardial laser revascularization in non-revascularizable coronary artery disease after 3 years follow-up [ssee comments]. Eur Heart J 1998; 19:1525-30. [PMID: 9820991 DOI: 10.1053/euhj.1998.1152] [Citation(s) in RCA: 46] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Abstract
BACKGROUND Transmyocardial laser revascularization is a new therapeutic option for end-stage coronary artery disease if no other cardiological or cardiosurgical intervention is possible. Data are few on how patients fare after more than 1 year follow-up. METHODS AND RESULTS From a total of 157 patients who were suggested for transmyocardial laser therapy in the years 1995-1997, 126 were judged to have non-revascularizable coronary artery disease (mean age 61.9 +/- 14 years, 80% men, mean left ventricular ejection fraction 46.2 +/- 17.1%). Sixty-six patients had a good clinical response to intensification of the antianginal therapy and were therefore treated further medically. In 60 patients with refractory angina, sole transmyocardial laser revascularization without cardiopulmonary bypass or additional grafts was performed. The transmyocardial laser revascularization group was 32% female; 78.3% patients had had bypass operations; the mean left ventricular ejection fraction was 53.6 +/- 15%. Eighty five percent of the transmyocardial laser revascularization patients had demonstrable ischaemic regions, as visualized by dipyridamol-MIBI scintigraphy. The percentage of patients with some hibernating myocardium in positron emission tomography studies was 70%. Good early relief of angina symptoms was experienced by patients who had undergone laser treatment. After 3 months the Canadian Cardiovascular Society class fell from 3.31 +/- 0.51 to 1.84 +/- 0.77 in 49 patients (P < 0.0001), but increased in the total group to 2.02 +/- 0.92 after 6 months (n = 47), to 2.26 +/- 0.99 after 1 year (n = 42), to 2.47 +/- 1.11 after 2 years (n = 38) and to 2.58 +/- 0.9 after 3 years (n = 19). MIBI/positron emission tomography data at rest and after 6 months was worse in patients in whom pre- and postoperative studies were complete (n = 22). The peri-operative mortality was 12% (n = 7: peri-operative myocardial infarction, low output syndrome, arrhythmia). Mortality after 1 and 3 years was 23% and 30%, respectively. The risk of transmyocardial laser revascularization was significantly elevated in patients with left ventricular ejection fraction < 40%. Late deaths (n = 9) were due to sudden arrhythmias or pump failure. There was a high rate of cardiac events and reinterventions in the transmyocardial laser revascularization group, including percutaneous transluminal coronary angioplasty in newly developed lesions (n = 7), valve replacement (n = 2), need for intermittent urokinase therapy (n = 5) and heart transplantation (n = 2). CONCLUSION Fifty percent of patients with non-revascularizable coronary artery disease submitted for transmyocardial laser revascularization can be stabilized medically. Transmyocardial laser revascularization led to a rapid early relief of symptoms, but with a trend towards worsening over time and showed a high peri-operative risk (> 10%) dependent on the pre-operative ejection fraction. Our data were in contrast to other published reports on the more beneficial effects of transmyocardial laser revascularization and should lead to further investigation of this experimental method. Transmyocardial laser revascularization should only be performed after failure of maximal anti-anginal therapy, and should be avoided when the left ventricular ejection fraction is < 40%.
Collapse
Affiliation(s)
- H Nägele
- Department of Cardiac Surgery, University Hospital Eppendorf, Hamburg, Germany
| | | | | | | |
Collapse
|
34
|
Nägele H, Dapper F, Rödiger W. [Status of intensified therapy and regionalized allocation of donor hearts in the management of patients with terminal heart failure]. Z Kardiol 1998; 87:676-82. [PMID: 9816649 DOI: 10.1007/s003920050226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND AND OBJECTIVE The medical management of heart failure improved greatly during the last decade. Heart transplantation (HTx) as surgical alternative is an established measure but operation numbers stagnated due to the lack of donor organs and still the 1 year mortality is about 20%. Rising numbers of new registrations led to long waiting lists with a high mortality rate. Solutions are intensified therapeutic concepts and improvements in organ allocation. This study was done to show if a combined intensified medical management and a regional donor allocation system may improve outcome in heart transplant candidates. PATIENTS AND METHODS A cohort of 396 elective candidates for heart transplantation from the years 1984-1997 without contraindications and at least in NYHA stage III at entry were investigated for total mortality, modes of death and the probability of heart transplantation. Patients were divided in two groups (group A: submitted from 1984-1994, n = 256, group B: 1995-1998, n = 150). RESULTS The groups were comparable in clinical and hemodynamic baseline characteristics. Patients of group B had a better long-term prognosis after 2 years (87% versus 73.5%, p = 0.009) and had a significantly lower rate of heart transplantation (HTx rate in group A and B after 2 years: 35% and 15%, p = 0.002). Only two patients died due to heart failure in the years 1995-1998 compared to 20 heart failure death from 1984-1994. The waiting time for a donor heart fell from 81.8 +/- 80 days in group A to 22.1 +/- 21 days in group B. The main problem is the unchanged sudden death rate in patients with stable hemodynamics prior to the event. CONCLUSIONS A combination of tailored medical therapy for heart failure plus regionalization of donor heart allocation with short waiting time seems to be the best way to treat patients with end-stage heart failure. A specialized cardiomyopathy program is necessary for such an approach. Sudden death in heart transplant candidates has to be studied more intensively.
Collapse
Affiliation(s)
- H Nägele
- Abteilung für Thorax-, Herz- und Gefässchirurgie, Universitätskrankenhaus Hamburg-Eppendorf
| | | | | |
Collapse
|
35
|
Nägele H, Döring V, Kalmár P, Schmidek G, Stubbe HH, Rödiger W. Long-term hemodynamic benefit of atrial synchronization with A2A2D or A2A2T pacing in sinus node syndrome after orthotopic heart transplantation. J Heart Lung Transplant 1998; 17:906-12. [PMID: 9773864] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023] Open
Abstract
BACKGROUND Exercise capacity after heart transplantation (HTx) may be limited by sinus node disease of the donor heart and atrioatrial dissociation. The role of pacemaker therapy in this setting is not well defined. The purpose of this study was to compare clinical and hemodynamic data of heart transplant recipients with acquired sinus node disease treated with atrial synchronized pacing and patients with other pacing modes or without pacemakers 1 year after operation. METHODS Our cohort comprises a total of 112 HTx recipients from the years 1984 to 1996. Atrial synchronized pacing was performed in 21 patients with donor sinus node disease and recipient sinus rhythm. There was no associated morbidity or death for the pacemaker implantation. Fourteen patients received a dual-chamber pacemaker programmed with a short atrioventricular-Delay in A2A2D mode (donor atrial pacing triggered by recipient atrial sensing or both atria stimulated on demand); in the last 6 consecutive patients a single-chamber pacemaker was implanted with two unipolar leads to the atria connected with a Y adapter programmed in A2A2T mode (both atria were sensed and stimulated by triggering each other). RESULTS Signals and thresholds remain stable over time. When clinical and hemodynamic data of 12 A2A2D/T patients with complete 1 year follow-up were compared to age- and sex-matched control HTx recipients with other pacing modes or without pacemakers, a significant benefit of atrial synchronization could be shown regarding rise in heart rate response to exercise (+38% vs 30% vs 16% at 50 watt), New York Heart Association classification (1.6 vs 1.8 vs 2.2), Roskamm staging (1.3 vs 2.5 vs 1.5), cardiac index at rest (3.2 vs 2.78 vs 3.1 L/min x m2), cardiac index at 50 watt (5.5 vs 4.5 vs 5.2 L/min x m2), stroke work at rest (51 vs 38 vs 42 pondmeter [PM]), stroke work at 50 watt (66 vs 48 vs 51 PM), pulmonary wedge pressure at rest (7 vs 13 vs 8 mm Hg) and pulmonary wedge pressure at 50 watt (14 vs 24 vs 18 mm Hg). CONCLUSION It is concluded that electromechanical synchronization of the atria was of long-term benefit in heart transplant recipients with recipient sinus rhythm and donor sinus node disease.
Collapse
Affiliation(s)
- H Nägele
- Chirurgische Klinik, Hamburg, Germany.
| | | | | | | | | | | |
Collapse
|
36
|
Nägele H, Appl U, Rödiger W. Implications of long-term pacemaker holter monitoring of patients with terminal heart failure submitted for heart transplantation. J Am Coll Cardiol 1998. [DOI: 10.1016/s0735-1097(98)80037-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
37
|
Abstract
OBJECTIVES LDL receptors of leukocytes play a key role in lipoprotein uptake, immunoregulation and the pathogenesis of atherosclerosis. Numerous studies with different methods of low reliability yielded conflicting results of its regulation in leukocyte subtypes. DESIGN AND METHODS LDL receptors of human leukocytes were measured with use of the monoclonal antibody C-7. Specific C-7 binding was detected by FACS analysis using phycoerythrin-anti-mouse-IgG. Parallel incubations with FITC-labelled anti-LEU 4 (CD 3), anti-LEU 12 (CD 19) and anti-MY 4 (CD 14) antibodies were used to distinguish C-7 binding of specific cell types (T-, B-lymphocytes and monocytes). RESULTS In contrast to monocytes, T and B-lymphocytes freshly isolated from healthy blood donors had no detectable binding capacity for C-7. After 24 and 48 h incubation of cells in a lipid-free medium, lymphocytes acquired some C-7 binding, albeit still much less than monocytes. Incubation with insulin for 24 h in a concentration of 0.5 microgram/mL led to an increase in C-7 binding for monocytes (up to 180%). Saturation experiments with the ligand suggests an increase in the number of receptors. In contrast the same insulin concentration inhibited C-7 binding of B- and T-lymphocytes by 35%. CONCLUSIONS FACS analysis using monoclonal antibodies seems to be a feasible method for the investigation of lipid metabolism in leukocytes. The LDL receptor expression and its regulation by insulin differs in circulating monocytes and lymphocytes.
Collapse
Affiliation(s)
- H Nägele
- Abt. für Herzchirurgie, Universitäts-Krankenhaus Hamburg-Eppendorf, Hamburg, Germany
| | | | | | | | | |
Collapse
|
38
|
Nägele H, Kalmar P, Nienaber CA, Rödiger W, Stubbe HM. [Place of trans-myocardial laser revascularization in treatment-resistant coronary heart disease]. Dtsch Med Wochenschr 1997; 122:1117-20. [PMID: 9340252 DOI: 10.1055/s-2008-1047736] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Affiliation(s)
- H Nägele
- Abteilung für Thorax-, Herz- und Gefässchirurgie, Universitätsklinik Eppendorf, Hamburg.
| | | | | | | | | |
Collapse
|
39
|
Abstract
OBJECTIVE Risk factors for the development of vasculopathy and malignancies as the most important causes of morbidity and mortality after heart transplantation are not well defined. METHODS Univariate and multivariate Cox regression analysis of the data derived from our 84 survivors of more than 3 months after orthotopic heart transplantation between 1984 and 1996. Measurement of carbonmonoxide-hemoglobin blood levels with an ABL 520 analyzer. RESULTS Recipient or donor age, the mode of immunosuppression, total-, LDL- and HDL-cholesterol, the HDL/LDL-ratio, triglycerides, hypertension, diabetes mellitus, CMV status and rejection episodes had no independent influence on total mortality or the occurrence of graft vasculopathy or cancer. By means of an intensive questionnaire (in case of deceased patients, by their relatives) and measurement of CO-Hb blood levels we detected a high rate of patients who smoked after transplantation (22/84 = 26%). Four patients confessed smoking after undergoing the blood test. Non-smokers were defined as denying it in the questionnaire and having CO-Mb levels < 2.5% in repeated measurements. All but one were smokers before heart transplantation. Mean consumption was 11 cigarettes per day. Five and 10 years survival was significantly reduced in smokers vs. non-smokers (37 vs. 80% and 10 vs. 74%, respectively, P < 0.0001). Survival curves diverged dramatically after 4 years of observation. Smokers had a higher prevalence of transplant vasculopathy as revealed by coronary angiography and/or autopsy (10/22 smokers vs. 2/62 non-smokers, P < 0.00001) and a higher rate of malignancies (7/22 smokers developed cancer, as compared to 4 cancers in 62 non-smokers, P = 0.0001). The primary site of cancer was the lung in 5/6 smoking and lymphoma in all non-smoking cancer patients. CONCLUSIONS Our data show that the prevalence of smoking after heart transplantation may be relatively high, especially in former smokers. Repeated measurements of CO-Hb could be helpful in its detection. Despite a relatively low cigarette count, smoking is a major risk factor of morbidity and mortality after heart transplantation (HTx). Approximately 4 years of exposure time is needed to uncover its negative influence. These findings should lead to aggressive smoking screening and weaning programs in every HTx center.
Collapse
Affiliation(s)
- H Nägele
- Department of Cardiovascular Surgery, University-Hospital Hamburg-Eppendorf, Hamburg, Germany
| | | | | | | |
Collapse
|
40
|
Nägele H, Kalmar P, Lübeck M, Marcsek P, Nienaber CA, Rödiger W, Stiel GM, Stubbe HM. [Transmyocardial laser revascularization--a treatment option for coronary heart disease?]. Z Kardiol 1997; 86:171-8. [PMID: 9173706 DOI: 10.1007/s003920050047] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Transmyocardial laser revascularization (TMR) is a new therapeutic principle for patients with coronary artery disease and no possibility of conventional revascularization with CABG or PTCA. The clinical value of the method is not known. Therefore we investigated all 46 patients treated with sole TMR in our center using clinical investigation, LV and coronary angiography, right heart catheterization, MIBI perfusion imaging and myocardial FDG-PET pre- and 6 months post TMR. 117 patients judged not suitable for conventional revascularization procedures were submitted for TMR. The indication for the procedure was reevaluated in every case. 52 patients (mean EF 41 +/- 16%) could be further treated by intensified anti-anginal medication, seven patients received bypass grafts, four patients had PTCA, three patients were listed for heart transplantation, and five patients had a combined CABG plus TMR. Only 46 (38% of the submitted patients, mean EF 55 +/- 15%) were accepted for sole TMR. CCS class of these patients was 3.3 +/- 0.4, mean age was 63.6 +/- 7.3 years, 70% were males. The postoperative mortality within 30 days was 5/46 (10.8%); 9/46 patients (19.5%) suffered from perioperative myocardial infarction. Other complications were ventricular fibrillation in two cases on the second postoperative day and a rupture of the spleen on the 14th postoperative day. 8/46 patients (17%) had wound infections. Survivors showed an improvement in their CCS class (1.9, 2.1, 1.9 after 3, 6 and 12 months, respectively, mean observation time 0.61 +/- 0.4 years). These patients were able to perform bicycle stress tests significantly longer (98 s +/- 9 pre versus 120 +/- 13 s post TMR, p = 0.01). Angiographic EF fell from 57.8% +/- 15% to 52.6% +/- 19% (p = 0.02) and the number of hypokinetic chords rose from 23.6 +/- 20.9% to 30.6 +/- 24.1% per patient (p = 0.008), predominantly in the inferior wall. Nuclear studies showed reduced myocardial perfusion and vitality after TMR. Four patients in the TMR group had reintervention (PTCA) because of progression of coronary sclerosis of native vessels. One patient had mitral valve replacement due to severe regurgitation. Kaplan-Meier analysis showed no significant difference in survival between the TMR and the medical group when stratified according to initial ejection fraction. Sudden death and congestive heart failure are the most important causes of mortality. Our data show that TMR improves symptoms and exercise performance of otherwise not treatable patients with diffuse coronary artery disease. Due to a lack of an improvement of cardiac perfusion, function or prognosis TMR should be used only in highly selected cases when conventional methods fail to improve patients symptoms.
Collapse
Affiliation(s)
- H Nägele
- Abteilung für Thorax-, Hertz- und Gefässchirugie Universitäts-Krankenhaus Hamburg-Eppendorf
| | | | | | | | | | | | | | | |
Collapse
|
41
|
von Knobelsdorff G, Goerig M, Nägele H, Scholz J. [Interaction of frequency-adaptive pacemakers and anesthetic management. Discussion of current literature and two case reports]. Anaesthesist 1996; 45:856-60. [PMID: 8967604 DOI: 10.1007/s001010050320] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
UNLABELLED We describe unexpected episodes of paced tachycardia in two patients with rate-responsive pacemakers during anaesthesia. Five months after a heart transplant and implantation of a pacemaker a 43-year-old patient suffered cardiac tamponade as a result of chronic pericarditis. The second case involved embolic occlusion of the femoral artery in a 33-year-old female patient previously operated on for tricuspid valve replacement and implantation of a pacemaker. In both cases induction of anaesthesia was performed with fentanyl, etomidate and vecuronium. Following intubation and mechanical ventilation, the heart rates (HR) of the two patients increased to 140 and 130 min-1 respectively. This was interpreted as a sign of inadequate anaesthesia, and therefore additional doses of fentanyl and etomidate were given, with no effect on the tachycardia. After exclusion of other possible reasons for this complication such as hypokalaemia, hypercapnia, hypoxaemia or allergic reactions, unexpected functioning of the rate-responsive pacemakers due to thoracic impedance changes was assumed. Minute ventilation was reduced, lowering paced HR in 3-5 min. CONCLUSIONS These case reports suggest that anaesthetic management affects the action of rate-responsive pacemakers, causing haemodynamic complications, and inadequate interventions by the anaesthesiologist. Thus, it is necessary for anaesthesiologists to make a preoperative evaluation of the underlying medical disease and the type of pacemaker in order to adjust anaesthetic management accordingly and to understand the haemodynamic responses that may occur during the perioperative period. Preoperative programming to exclude the rate-responsive function is advised.
Collapse
Affiliation(s)
- G von Knobelsdorff
- Abteilung für Anästhesiologie, Universitäts-Krankenhaus Eppendorf, Hamburg
| | | | | | | |
Collapse
|
42
|
Niendorf A, Nägele H, Gerding D, Meyer-Pannwitt U, Gebhardt A. Increased LDL receptor mRNA expression in colon cancer is correlated with a rise in plasma cholesterol levels after curative surgery. Int J Cancer 1995; 61:461-4. [PMID: 7759150 DOI: 10.1002/ijc.2910610405] [Citation(s) in RCA: 44] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
It is currently under debate whether the low serum cholesterol levels that are frequently observed in cancer patients represent a risk factor for/or, rather, are a consequence of the tumour. We postulate that malignant tumours are directly involved in an increased catabolism of cholesterol-rich low-density lipoprotein (LDL) particles. In a prospective study of 25 patients with colorectal carcinoma, we measured intraindividual shifts in serum cholesterol levels after surgery, and the expression of LDL-receptor mRNA in surgically removed specimens. A significant rise in plasma cholesterol levels was observed in patients 3 and 12 months after curative surgery, but not after non-curative surgery. In human colon carcinoma tissues LDL receptor mRNA expression, as determined by competitive reverse-transcriptase-polymerase-chain reaction, was found to be significantly increased when compared to tissues from the tumour-free margin (median values, 1.2 x 10(6) vs. 2.0 x 10(5) molecules/micrograms total cellular RNA, respectively, n = 17). The extent of LDL-receptor mRNA expression positively correlated to the percentage rise of plasma cholesterol levels 3 months (n = 7, r = 0.8763) and 12 months (n = 6, r = 0.9181) after curative surgery. This finding provides in vivo evidence that the tumour tissue itself contributes to decreased plasma cholesterol levels in patients suffering from colorectal carcinomas. It supports the hypothesis that low cholesterol levels in cancer patients are a consequence, and not the cause, of the malignancy.
Collapse
Affiliation(s)
- A Niendorf
- Institute of Pathology, University of Hamburg, Germany
| | | | | | | | | |
Collapse
|
43
|
Niendorf A, Stang A, Beisiegel U, Peters A, Nägele H, Gebhardt A, Kuse R. Elevated lipoprotein(a) levels in patients with acute myeloblastic leukaemia decrease after successful chemotherapeutic treatment. Clin Investig 1992; 70:683-5. [PMID: 1392445 DOI: 10.1007/bf00180286] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Twenty-two patients with acute myeloblastic leukaemia (AML) were studied to investigate disease-associated changes in lipid metabolism. Lipoprotein (a) [Lp(a)] levels were found to be elevated at the time of diagnosis (median 23 mg/dl; 41% of patient group had levels greater than 25 mg/dl) and diminished after successful chemotherapeutic treatment in 9 of 10 cases, with a maximum decrease from 56 to 10 mg/dl. In contrast, reduced levels of total cholesterol, low density lipoprotein (LDL) and high density lipoprotein (HDL) (medians 137, 87 and 20 mg/dl, respectively) were observed at the time of diagnosis. Cholesterol and HDL levels increased in all 10 and LDL in 9 cases in which complete remission was achieved. These data suggest that the catabolism of LDL-cholesterol might be even more enhanced than assumed to date. Furthermore, it indicates that the Lp(a) level in acute myeloblastic leukaemia is influenced either directly or indirectly by the leukaemic blasts.
Collapse
Affiliation(s)
- A Niendorf
- Institut für Pathologie, Universitätskrankenhaus Eppendorf, Universität Hamburg
| | | | | | | | | | | | | |
Collapse
|
44
|
Krone W, Nägele H. Metabolic changes during antihypertensive therapies. J Hum Hypertens 1989; 3 Suppl 2:69-73; discussion 74. [PMID: 2575177] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
There is controversy whether various classes of antihypertensive drugs can reduce significantly cardiovascular morbidity and mortality in primary prevention. A failure to show this in many studies was attributed, at least in part, to deleterious effects of these drugs on lipid metabolism. Especially adrenergic antihypertensives cause marked effects on lipoprotein levels in plasma. A review of the literature revealed that beta-blockers increase triglycerides and VLDL (very low density lipoprotein)-cholesterol and may lower plasma HDL (high density lipoprotein) levels. In contrast alpha 1-adrenergic inhibitors like prazosin, doxazosin and terazosin lower triglycerides, total cholesterol, LDL (low density lipoprotein)- and VLDL-cholesterol and increase plasma HDL levels. The mechanisms by which alpha- and beta-blockers may produce the observed effects on plasma lipids and lipoproteins are not well understood. It has been shown in our laboratory that the activity of the LDL receptor of peripheral cells, a major determinant of cholesterol levels in plasma, is regulated by catecholamines via alpha 2- and beta 2-adrenergic receptors. Accordingly, blockade of these adrenoceptors with alpha- and beta-adrenergic antagonists can reverse the catecholamine effect. In addition these agents may affect lipoprotein lipase, lecithin cholesteryl acyltransferase and cholesterol ester hydrolase. These data may explain, at least in part, the plasma effects. However, long-term studies are needed to clarify the clinical value of antihypertensives with different metabolic profiles.
Collapse
Affiliation(s)
- W Krone
- Medizinische Kernklinik und Poliklinik, Universitäts-Krankenhaus Eppendorf, Hamburg, West Germany
| | | |
Collapse
|
45
|
Krone W, Klass A, Nägele H, Behnke B, Greten H. Effects of prostaglandins on LDL receptor activity and cholesterol synthesis in freshly isolated human mononuclear leukocytes. J Lipid Res 1988; 29:1663-9. [PMID: 2854153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
The effects of prostaglandin (PG) E1, PGE2, the stable prostacyclin analogue Iloprost, and PGF2 alpha on low density lipoprotein (LDL) receptor activity and cholesterol synthesis were investigated in freshly isolated human mononuclear leukocytes. Incubation of cells for up to 45 hr in a lipid-free medium resulted in an increase in the rate of cholesterol synthesis from [14C]acetate and the high affinity accumulation and degradation of 125I-labeled LDL. Addition of PGE1 in increasing concentrations to the incubation medium inhibited cholesterol synthesis and the specific accumulation and degradation of 125I-labeled LDL; at a concentration of 10 microM, the inhibitions were 61%, 70%, and 67%, respectively, after an incubation of 20 hr. The effects of PGE2 and Iloprost were similar. The action of the prostaglandins on LDL receptor activity appeared to be mediated by a decrease in the number of LDL receptors and not by a change in the binding affinity. The prostaglandins yielded sigmoidal log concentration-effect curves. In contrast, PGF2 alpha had no influence on cholesterol synthesis or LDL receptor activity up to a concentration of 10 microM. PGE1, PGE2, and Iloprost, but not PGF2 alpha, led to an increase in the concentration of intracellular cyclic AMP. Dibutyryl cyclic AMP mimicked the effects of the E-prostaglandins and Iloprost on the LDL receptor activity. The results suggest that PGE1, PGE2, and prostacyclin affect LDL receptor activity and cholesterol synthesis and, therefore, may play a role in the regulation of cholesterol homeostasis and in the development of atherosclerosis.
Collapse
Affiliation(s)
- W Krone
- Medizinische Kernklinik and Poliklinik, Universitäts-Krankenhaus Eppendorf, Hamburg, FRG
| | | | | | | | | |
Collapse
|
46
|
Krone W, Klass A, Nägele H, Behnke B, Greten H. Effects of prostaglandins on LDL receptor activity and cholesterol synthesis in freshly isolated human mononuclear leukocytes. J Lipid Res 1988. [DOI: 10.1016/s0022-2275(20)38406-6] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
47
|
Abstract
There is good epidemiologic evidence that hypertension is associated with a high risk of cardiovascular disease. However, primary intervention trials have failed to demonstrate that a reduction in blood pressure in hypertensive patients reduces morbidity and mortality from cardiac events. Since various antihypertensive drugs adversely affect lipoprotein metabolism, these drugs may increase associated coronary risk and offset the beneficial effects of lowering blood pressure. This article reviews the effects of various antihypertensive drugs on plasma lipids, lipoproteins, and apolipoproteins. They can be summarized as follows: thiazide-type diuretics cause a marked elevation of plasma triglycerides and very low-density lipoprotein (VLDL) and minor increases in total cholesterol and low-density lipoprotein (LDL), but have little effects on high-density lipoprotein (HDL). The nonselective beta-blockers do not significantly affect total cholesterol and LDL, but increase total triglycerides and VLDL and decrease HDL. The changes in plasma lipids and lipoproteins caused by cardioselective beta-blockers and beta-blockers with intrinsic sympathomimetic activity are qualitatively similar but less pronounced. Calcium antagonists and angiotensin-converting enzyme inhibitors appear to have no significant effects on plasma lipids. alpha 1-Inhibitors reduce total triglycerides, total cholesterol, VLDL, and LDL and increase HDL. The possible mechanisms by which antihypertensive drugs affect cellular lipid metabolism (e.g., LDL receptor, lipid synthesis, lipoprotein lipase, lecithin cholesteryl acyltransferase, acylcholesteryl acyltransferase, and cholesteryl ester hydrolase) are described. The clinical significance of changes in blood lipids and cellular lipid metabolism caused by antihypertensive drugs is not yet totally clear. Nevertheless, before antihypertensive drug treatment is initiated, blood lipid levels should be measured to identify preexisting hyperlipidemia.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- W Krone
- Medizinische Kernklinik und Poliklinik, Universitäts-Krankenhaus Eppendorf, Hamburg, West Germany
| | | |
Collapse
|